Growth Inhibition of KRAS‑�and EGFR‑mutant Lung Adenocarcinoma by Cosuppression of STAT3 and the SRC/ARHGAP35 Axis

Oncology Reports - Greece
doi 10.3892/or.2018.6536
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

MerTK Mediates STAT3–KRAS/SRC-signaling Axis for Glioma Stem Cell Maintenance

Artificial Cells, Nanomedicine and Biotechnology
MedicineBiotechnologyBiomedical EngineeringPharmaceutical Science
2018English

P010 Relationship Between EGFR and KRAS Mutation and the Clinicopathologic Features of Early Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ΙκΒ Kinase Α Is Required for Development and Progression of KRAS-mutant Lung Adenocarcinoma.

Cancer Research
Cancer ResearchOncology
2018English

MET-EGFR Dimerization in Lung Adenocarcinoma Is Dependent on EGFR Mtations and Altered by MET Kinase Inhibition

PLoS ONE
Multidisciplinary
2017English

SKA3 Promotes Lung Adenocarcinoma Metastasis Through the EGFR-PI3K-Akt Axis

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2020English

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status

PLoS ONE
Multidisciplinary
2013English

P14ARF Inhibits the Growth of Lung Adenocarcinoma Cells Harbouring an EGFR L858R Mutation by Activating a STAT3-dependent Pro-Apoptotic Signalling Pathway

Oncogene
Cancer ResearchGeneticsMolecular Biology
2012English

P2.01-09 Targetable Genomic Alterations in KRAS Mutant Lung Adenocarcinoma by Targeted Next Generation Sequencing

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Inhibition of Hsp90 Down-Regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel

Cancer Research
Cancer ResearchOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy